202 related articles for article (PubMed ID: 32803870)
1. Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.
Karachiwala H; Tilley D; Abdel-Rahman O; Morris D
Clin Respir J; 2021 Jan; 15(1):36-41. PubMed ID: 32803870
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
5. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
[TBL] [Abstract][Full Text] [Related]
6. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Hatfield LA; Huskamp HA; Lamont EB
J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
8. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
9. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.
Kim H; Choi E; Heo MH; Kim JY; Park KU
Oncology; 2022; 100(6):313-319. PubMed ID: 35390786
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Salgia R; Stille JR; Weaver RW; McCleod M; Hamid O; Polzer J; Roberson S; Flynt A; Spigel DR
Lung Cancer; 2017 Mar; 105():7-13. PubMed ID: 28236984
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.
Kim E; Biswas T; Bakaki P; Dowlati A; Sharma N; Machtay M
Pract Radiat Oncol; 2016; 6(5):e163-e169. PubMed ID: 27142494
[TBL] [Abstract][Full Text] [Related]
12. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
[TBL] [Abstract][Full Text] [Related]
13. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Curr Oncol; 2019 Jun; 26(3):e372-e384. PubMed ID: 31285682
[TBL] [Abstract][Full Text] [Related]
14. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer.
Sama S; Kerrigan K; Sinnott JA; Puri S; Akerley W; Haaland B; Patel S
Cancer Treat Res Commun; 2023; 35():100686. PubMed ID: 36736060
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
18. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
20. Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy.
Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):658-666. PubMed ID: 30007803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]